WENDY ADAMSGeneral Manager

Galderma Canada Inc.

Wendy Adams began her career in pharmaceutical sales in the Ottawa area after graduating from

Carleton Univeristy in 1988. Wendy moved to Toronto to join the marketing team at Merrell Dow

Pharmaceuticals, running brands such as Nicorette, Nicoderm and Seldane. She joined Galderma

Canada Inc. over 17 years ago as the Product Manager for Cetaphil. Wendy has held various sales

and marketing positions with Galderma prior to becoming the General Manager in 2008.

PETER BRENDERSPresident and CEO

BIOTECanada

Peter Brenders joined BIOTECanada as President & CEO in February 2005. Previously, Peter

worked in corporate affairs in senior management roles at Genzyme Canada and Schering-Plough

Canada. Peter has also worked in the Ontario Ministry of Health and in the health consulting practice

at KPMG. Peter is a member of the Department of Foreign Affairs and International Trade’s Life

Sciences Advisory Board, an Industry Advisor for the Atlantic Canada Opportunity Agency’s Atlantic

Innovation Fund and a member of the Advisory Board for the National Research Council’s (NRC)

Institute for Marine Biosciences and Institute for Nutrisciences and Health. He received his MBA in

Health Services Management from McMaster University and his Honours BSc in Pharmacology and

Toxicology from the University of Western Ontario.

JEFF DOANDirector, Business Development

Nycomed, A Takeda Company

Jeff Doan started his career in pharmaceuticals in 1995. Jeff has held various roles—as a Sales

Representative for two years, a Sales Manager for three years, a Customer Relationship Manager

for two years, Marketer for four years and has spent the last five years in Business Development.

Jeff started with Marion Merrell Dow (Sanofi), but spent most of his career at Nycomed (Byk Canada,

Altana, Nycomed and soon Takeda).

JILL DONAHUE, Hba, MadEdSpeaker, Writer, Behaviour Change Consultant to Pharma

Excellerate

Jill Donahue Hba, MAded, author of PERSUASION Rx: How to Influence Ethically (CCPE’s most popular course), is

fascinated with behaviour change in healthcare. Through her energizing keynotes, workshops, coaching and consulting,

she brings the ah-ha’s to how to influence others (health care professionals, patients, your audience, your team, even your

2012 Faculty

spouse). From ‘uninterested’ to ‘on board’ she has tips for every step of the way.

While Jill brings a strong academic background to her work, what marvels her pharma clients is

her talent to translate the theory of behaviour change to practical application to help pharma

professionals from all departments influence more effectively. Says one client: “Jill is the guru of

behaviour change in pharma.”

Founder and chair of Bricks and Books (a charity event built by pharma for pharma

www.bricksandbooksevent.com), Jill and her volunteer team are creating good news headlines

for our pharma community. Join them on Oct. 3, 2012 and help build another school.

RICHARD FAJZELGeneral Manager, Oncology Business Unit - Canada

Pfizer Canada Inc.

Richard Fajzel is currently General Manager, Oncology Business Unit - Canada, a position he has

held since January 2009. Previously, he was Director of Sales for the Specialty Market including

oncology, AI/HIV and Ophthalmology.

Richard has 20 years of pharmaceutical industry experience and has been with Pfizer Canada since

1996. Throughout Richard’s 13-year career at Pfizer, he has worked in Business Development,

Marketing and Sales, touching upon multiple therapeutic areas such as Specialty, Respiratory,

Urology and Pain and Inflammation.

From 2001 to 2008, he gained extensive oncology experience as Director of Marketing followed by Director of Sales for the

Specialty Market division. During this time he led the Specialty Business Model development for the Oncology-HIV portfolio,

successfully oversaw the launch of Sutent and developed the Institutional Key Account Management division.

Richard holds a Bachelors of Arts from McGill University as well as a Master of Business Administration from Concordia

University, where he was on the Dean’s Honour List. In addition, he established the MBA student practicum program with the

McGill School of Management, where he was also a lecturer.

Richard is married and a father of three kids. In his spare time he enjoys skiing with his children, reading and working out.

PAT FORSYTHENeuroscience Business Unit Director

Allergan Inc.

Pat Forsythe, Neuroscience Business Director at Allergan Canada, has over 20 years of sales and

marketing experience in the Canadian Pharmaceutical industry in a range of therapeutic areas from

Specialty Biotech to traditional Primary Care. Prior to Allergan, Pat worked with Altana Pharma in the

Gastroenterology and Respiratory categories and with Roche in Hepatitis, Cardiovascular and

Antimicrobials. He started his career with the Upjohn Company of Canada.

Pat’s sales and marketing career has been characterized by a strong focus on a customer centric

approach balanced with the reality of business needs. His work has been characterized by constant

innovation and an entrepreneurial approach to meeting customer needs.

Pat has been involved in 12 product launches and is currently working with his team to prepare for additional launches through

to 2014.

GREG GAUTHIERPresident

CPDN

Greg Gauthier is currently the President and CEO of Canadian Pharmaceutical Distribution Network.

Greg has over 25 years of experience in the healthcare market having held senior management roles

with companies like AmerisourceBergen, Cardinal Health, Siemens and Baxter Healthcare, in both

Canada and the US. Prior to CPDN, Greg was Vice President of Urodynamix Technologies, a public

start-up medical device company located in Vancouver,B.C. Greg has also consulted with companies

like Kohl and Frisch, Patheon, and the Ministries of Health in New Brunswick and Ontario on various

business development and private/government alliances in the pharmaceutical, medical

technologies, hospital and long term care markets. Greg currently lives in Peterborough, Ont. with his

wife Leslie and has two children attending the University of Western Ontario. Greg attended the University of Waterloo and

graduated in Economics.

DOMINIQUE GILBERTSenior Director, Market Access and Health Outcomes

Lundbeck Canada Inc.

Dominique Gilbert is a seasoned professional with over 20 years of experience in the pharmaceutical

industry. Throughout Dominique’s career, he has been involved in sales, marketing and market

access, and has held a number of senior positions in these various functions. He was one of a

handful of individuals who joined Lundbeck Canada 16 years ago as the company was establishing

its Canadian affiliate. For the past six years, he has led the Market Access function at Lundbeck

Canada and built a solid team of professionals with whom he has successfully improved

reimbursement of the company’s flagship product and by so doing significantly impacted the

performance of the organization. Dominique reports to the President & General Manager and is part

of the company's management team. He is results-oriented with strong leadership and communication skills.

Dominique has a deep understanding of the issues facing the pharmaceutical industry and of the need to work together with all

stakeholders to ensure a dynamic and sustainable future for innovation in biopharmaceutical in Canada.

JOHN HASLAMCountry Manager

Alexion Pharmaceuticals

John Haslam’s career in the pharmaceutical/biotechnology industry spans 20 years. John obtained

his BSc in Microbiology from theUniversity of Toronto and his MBA from McMaster. He has worked

in positions of increasing responsibility in Sales and Marketing at Bayer Healthcare, Hoffmann La-

Roche and Biogen Idec. In 2006, John started his own company, SBP Launch Specialists, assisting

companies to launch products into the Canadian market. In 2009, John was appointed President and

General Manager of Alexion Pharma Canada where he is currently leading the Canadian operations.

Alexion Pharma Canada specializes in products for rare diseases of which the lead compound is

Soliris, used to treat the rare blood disease known as Paroxysmal Nocturnal Hemoglobinuria or PNH.

ROBIN HUNTERVice President, Critical Care

LEO Pharma

Robin Hunter has over 18 years of experience in the Pharmaceutical industry and joined LEOPharma in 2010 as the Vice President of Sales & Marketing. In this role he is responsible for leadinga high performing sales and marketing team to exceed targets and for implementing the LEO missionof helping people achieve healthy skin.

Prior to LEO, Robin spent 12 years at Roche, most recently as a Business Unit Director in Oncology.He also has several years of experience building Key Account Management teams and collaboratingwith the Canadian College of Health Leaders

He is a past board member of Toronto's Ronald McDonald House, graduate of the University of Waterloo and currently lives inToronto with his wife Julija and their three children.

IAN JOHNSONPrincipal

IMS Brogan

Ian Johnson joined Brogan (now known at IMS Brogan) in November 2009 to set up a new business

group which focuses on integrating primary market research with secondary data in the

pharmaceutical market. Previously, Ian led the Canadian group of P\S\L Market Research Canada

as its President. Prior to moving on to the agency/supplier side of the business, Ian spent 20 years

working for two major pharmaceutical companies (Bristol-Myers Squibb and Novartis).

Ian joined BMS as a sales representative, winning many awards including Rookie of the Year and

National Sales Rep of the Year. During his field-based time at BMS, Ian worked in a variety of roles

including Sales Trainer, Health Policy work in Saskatchewan, Hospital Rep and Field Marketing

Associate. He later became the most senior product manager on Pravachol, Canada’s 4th largest

pharmaceutical product.

After leaving BMS, Ian joined Novartis, as Brand Manager for Diovan, moving it from the slowest growing drug in its class to the

#1 ARB in Canada. During this time, Ian progressed from Product Manager to Director of Marketing leading the CV franchise,

after which he moved to set up the Business Development and Licensing group at Novartis. During this time, Ian managed the

in-licensing, divestments and co-promotional agreements for a number of different products.

Ian holds a Bachelor of Science degree from the University of Saskatchewan and an MBA from Herriot-Watt University,

Edinburgh, United Kingdom.

HELEN KALRAAssociate Managing Parnter

The Pangaea Group

Helen Kalra began her career in pharma over 20 years ago as a sales representative and quickly

progressed through various roles in business development, product management and then into a

leadership role in Marketing. Before joining Pangaea she was Marketing Director for the

Gastrointestinal franchise at AstraZeneca Canada Inc.

She has managed through a range of business situations including corporate restructures, co-

promotions, patent expiry, mega-brand launches, hospital strategy for primary care brands and

significant changes to reimbursement policy. She has led brand and cross-functional teams that

managed the life-cycle of small and large brands in a variety of therapeutic areas. She also led the

development and implementation of initiatives or processes that were used as models across

organizations such as launch models, assessments of public sector policy and new strategic

planning processes.

Helen has an undergraduate degree in Human Biology with a Biomedical Minor from the University of Guelph. She has

represented Canada in rugby and retired from the sport as Captain of the Canadian Women’s Team.

Helen brings to Pangaea her experience in market, product and portfolio assessments and launching brands in a variety of

therapeutic areas including cardiology, mental health/schizophrenia, pain control/anesthesia, respiratory and gastroenterology.

The common underpinning of her success is a proven track record in developing enduring partnerships with key customers.

KEVIN LESHUKVice President and General Manager

Celgene

Kevin Leshuk began his career in the pharmaceutical/biotech industry in the early 1990’s as an Oncology sales representative

with Adria Oncology. He is currently Vice President and General Manager for Celgene Inc, a wholly owned subsidiary of Celgene

Corporation, a multinational biopharmaceutical company focused on the discovery, development and commercialization of

products for the treatment of cancer and other severe, immune-inflammatory conditions.

Kevin has had the tremendous good fortune to work within some of the leading Canadian

pharmaceutical companies; providing valuable development and personal insights into multiple

disease areas. Through his career, Kevin has had significant management accountability within

both Primary and Specialty Sales, Marketing, Key Account Management and more recently Market

Access.

DR. STUART MADDIN

Vancouver

Stuart Maddin is a member of the Department of Dermatology & Skin Science, UBC. He has been

an advisor to HPB (Ottawa), USP (Rockville), WHO (Geneva), and AAD-FDA Liaison Task Force.

Dr. Maddin is the first Canadian to serve as a director of the American Academy of Dermatology

and to be elected to the International Committee of Dermatology (ICD)— later appointed Secretary-

General of the ICD (ILDS). He was also secretary and president of the Canadian Dermatology

Association and VP of the American Dermatological Association. Dr. Maddin is Editor-in-Chief of

the Skin Therapy Letter and co-founder/chairman of SkinInformation.com. He has authored over 60

articles in dermatology and is the founder/director of the Dermatology Update Symposium, now in

its 28th year.

MARK McELWAINVice President, Account Services

kbs+p Toronto

Mark McElwain is Vice President, Account Services at kbs+p Toronto (formerly Allard Johnson

Communications) where he heads the wellness division, which develops advertising and interactive

programs for pharma and other healthcare clients.

Prior to joining Allard Johnson, Mark was Commissioner/CEO of the Pharmaceutical Advertising

Advisory Board (PAAB). During his tenure at PAAB, he worked to improve service turnaround

times, reform the complaints process, and together with stakeholders to raise PAAB’s profile in

industry self-regulation.

Mark started his career as a health economist and worked at senior levels in both federal and Ontario governments. He has

master’s degrees from the London School of Economics and from Queen’s University.

EILEEN McMAHONPartner

Torys LLP

Eileen McMahon is Co-Chair of the Intellectual Property and Food and Drug Regulatory practices

at Torys LLP. Torys is a law firm with offices in Toronto, New York and Calgary. Eileen and her firm

act for many leading pharmaceutical, biotechnology and medical device companies. Eileen is a

lawyer and is a registered patent agent in the United States and Canada.

DR. SHAFIQ QAADRIGeneral Practitioner

MPP (Ontario), Parliamentary Assistant to the Minister of Health Promotion

Dr. Shafiq Qaadri is a Toronto family physician, Continuing Medical Education (CME) lecturer,

medical writer and broadcaster. He wrote a column for doctors in The Medical Post, and currently

writes for The Globe and Mail, Canada’s national newspaper. He has logged more than 1,000

radio and TV shows across Canada.

He is a Designated Medical Practitioner (DMP) of the Government of Canada, and a leader in

making health information understandable to the public and physicians alike.

Dr. Qaadri has delivered more than 180 medical lectures, and published more than 700 articles,

on a wide range of topics. He is a presenter for the Heart and Stroke Foundation, Canadian

Diabetes Association, and the Ontario Lung Association.

He is the author of the international-selling health manual for baby-boomer men, The Testosterone Factor: A Practical Guide to

Vitality and Virility, Naturally, which is now available in five countries in four languages.

A long-time advocate of quality public healthcare and a compassionate society, Dr. Qaadri was elected to the Government of

Ontario as the Member of Provincial Parliament (MPP) for Etobicoke North in October 2003. He was re-elected as the MPPfor

Etobicoke North in October 2007. He is the Chair of the Parliamentary Standing Committee on Social Policy.

Educated at Upper Canada College, he graduated from the University of Toronto Medical School in 1988. During his academic

career, he won numerous awards and scholarships, including a Canadian National Debating Championship, an English-

Speaking Union Essay Prize to Oxford University, a Medical Research Council Scholarship in Clinical Neurosurgery, and a

Senator Thompson Fellowship at the University of Pennsylvania.

He is a member of the Healthcare Policy Group of the Council of State Governments (New York), an American-based think-

tank which offers counselling to government, advising states and organizations navigating the waters of universal coverage.

ANDREW SENIORPresident

Target Pharma Marketing

Andrew Senior is the founder and president of Target Pharma Marketing Inc, a consulting firm

specializing in pharmaceutical marketing. The focus of the company is to help clients find

opportunities for their brands, and efficiencies in their sales and marketing efforts. Since its

inception the company has worked for pharmaceutical and biotech companies, data suppliers and

advertising agencies. Services include strategic market analysis, meeting facilitation, and

business development.

Andrew brings a unique combination of analytics and creativity to pharma marketing. He is a

published author in both science and marketing; his first book 101 Questions, A Handbook for

Opportunities in Pharmaceutical Marketing was published in 2002. He has also authored numerous journal articles on corporate

branding, brand positioning and tactical innovations. He has facilitated over 50 advisory board and brand planning meetings

and been a guest lecturer on pharmaceutical marketing at Brock, McMaster, and York Universities.

MITCHELL SHANNONCEO

Chronicle Companies

Mitchell Shannon is CEO and co-founder of Chronicle Companies, organizing corporate partner of

the National Pharmaceutical Congress. Chronicle Companies has served Canada’s Life Sciences

industry since 1995 though its business-to-business publications, The Chronicle of Healthcare

Marketing (TM) and Drug Rep Chronicle (TM). This event marks the 10th annual presentation of

the Canadian Healthcare Marketing Awards, a program initiated by Chronicle to honor those who

build and inspire our industry.

Mitch is the publisher of Chronicle's nationally distributed journals for the health specialties, including

the brand-new Chronicle of Cosmetic Medicine + Surgery. He is a founding director of the Chronic

Obstructive Pulmonary Disease Association, and of D-Minus: The Partnership to Prevent Diabetes, an advocacy group for patients

at risk. He continues to entertain and incite readers from more than 70 countries, at last count, through his blog,

www.mitchellshannon.com.

RUSSELL WILLIAMSPresident

Canada’s Research-based Pharmaceutical Companies (Rx&D)

Russell Williams is a passionate advocate for innovation in health care and in economic

development. Since joining Rx&D in March 2004, Mr. Williams has promoted policies that improve

patient outcomes by expanding patient choice and access to new medicines and vaccines. He

works tirelessly to ensure that Canada is a world leader in attracting biopharmaceutical

investments, which are key components of the knowledge-based economy.

Under Mr. Williams’ leadership, the association’s Code of Ethical Practices has been significantly

enhanced to ensure that all member companies adhere to the highest standards of ethics. He has

participated actively in numerous provincial working groups and task forces aimed at improving the

partnership between industry, governments and stakeholders.

Prior to joining Rx&D, Mr. Williams had a successful career in provincial politics and community service. For fifteen years, he

represented the Montreal riding of Nelligan in the National Assembly of Quebec. During his career as Liberal MNA, he led

numerous public policy debates on important and complex issues, such as the role of government in research and development

(R&D), compensation for victims of contaminated blood, linguistic policy, access to services for the disabled, and pre-hospital

emergency services. He is well known for his dedication and perseverance as an advocate for individual rights and government

services focused on the needs of its citizens. He continues active volunteer involvement in palliative care.